|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Mentor Corporation (MNTR) Capital Chairman Highlights $0.91/Share Non-GAAP Gains from Cancer Portfolio Appreciation
1/25/2010 12:13:07 PM
SAN DIEGO--(BUSINESS WIRE)--Mentor Capital, Inc. (Pink Sheets:MNTR) Chairman, in his 2009 Letter to Shareholders, outlined $0.91/sh gains. On a mark-to-market basis Mentor Capital projected earnings per basic outstanding share for 2009 would be approximately 91 cents per share. On a fully diluted basis, Company mark-to-market earnings would be approximately 29 cents per average share equivalent for the year. The majority of Mentor Capital mark-to-market gains, used internally to judge management performance, are in the appreciation of cancer immunotherapy stock holdings. On a GAAP basis, these gains will not be recognized until later. Not counting these portfolio gains, the GAAP earnings per basic share, on a more precise but still not audited basis, would be an 18 cent loss, generally reflecting Company operating expenses.
|
|
|
|
|
|
|
|
|
|
|